University of Malaya Medical Centre | Department of Rheumatology

Research site

(Unclaimed)

Location

CIC Menara Timur UMMC, Kuala Lumpur, Selangor, Malaysia

Site insights

Top conditions

Top treatments

BI 685509

Vincristine

6-Mercaptopurine

Methotrexate

Prednisolone

Empagliflozin

Cytarabine

Pembrolizumab

Odevixibat

Cyclophosphamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 56 total trials

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Active, not recruiting

Scleroderma, Systemic

Drug: Placebo

Drug: Avenciguat (BI 685509)

Locations recently updated

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Drug: ABP 234

Drug: Pembrolizumab (EU)

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This...

Active, not recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)

Drug: Cetuximab

Drug: Ezabenlimab

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of...

Active, not recruiting

HIV Infections

Drug: Darunavir

Drug: NRTIs

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study....

Enrolling

Kidney Disease, Chronic

Drug: Placebo matching BI 690517

Drug: Empagliflozin

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with...

Active, not recruiting

Biliary Atresia

Drug: Odevixibat

Drug: Placebo

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection...

Enrolling

SARS-CoV-2 Infection

Drug: Azvudine

Drug: Placebo

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling

Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Drug: Placebo matching survodutide

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease

Objectives:Primary: To demonstrate the safety of allogeneic UC-MSCs administered by injection for complex perianal fistulas in patients with Crohn's...

Enrolling

Fistula in Ano

Perianal Fistula Due to Crohn's Disease

Biological: PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells

The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exa...

Begins enrollment in 1 month

Bronchiectasis

Drug: Placebo matching BI 1291583

Drug: BI 1291583

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling

Chronic Kidney Diseases

Dialysis-dependent Kidney Failure

Drug: Rivaroxaban 2.5 Mg Oral Tablet

Other: Placebo